Aug 11, 2022 / 07:30PM GMT
Ben Shim - Canaccord Genuity - Analyst
(audio in progress) everybody and welcome to our afternoon session of the 42nd Annual Canaccord Genuity Growth Conference. I'm Ben Shim, a member of the biotech research team. It's my pleasure to introduce the management team of X4 Pharmaceuticals, Dr. Paula Ragan, CEO; and Adam Mostafa, CFO. Welcome and thanks for joining us.
Paula Ragan - X4 Pharmaceuticals, Inc. - CEO & President
Thank you so much for having us. And it's a great conference and place to be in person with everyone. And looking forward to the connection today.
Questions and Answers:
Ben Shim - Canaccord Genuity - AnalystFor those who are new to the X4 story, can you maybe give us a brief background on what WHIM -- that's W-H-I-M -- syndrome is and how your drug, mavorixafor, is positioned to help this patient population?
Paula Ragan - X4 Pharmaceuticals, Inc. - CEO & President
Sure. So I'll start. So the company is really focused on making a difference